Hospira Recalls Propofol Injectable Emulsion Due to Particulate Matter
Hospira Inc. is recalling 70,450 vials of Propofol Injectable Emulsion because visible particles were found in the glass during inspection.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a severity score of 4 (Severe) according to the rubric, as it may cause temporary or medically reversible adverse health consequences.
Plain-English summary
Hospira Inc. is recalling 70,450 vials of Propofol Injectable Emulsion, 1%, 200 mg/20 mL (10 mg/mL), 20 mL single patient infusion vials. The product is identified by Lot # 27-570-DJ and has an expiration date of 03/01/15. The recall was initiated because visible particles embedded in the glass were identified during a retain sample inspection.
The affected product is distributed nationwide. It is a prescription-only medication used for general anesthesia. The recall is classified as FDA Class II, indicating that use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences.
Healthcare facilities and pharmacies should stop using the affected product and contact Hospira Inc. for further instructions. Consumers should not use the product and should return it to the point of purchase or contact their healthcare provider.
The recalled product
- Product
- PROPOFOL (PROPOFOL)
- Brand
- PROPOFOL
- Manufacturer
- Hospira Inc.
- Category
- Drug — General Anesthesia
- Hazard
- Affected units
- 70,450
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 27-570-DJ
- Exp 03/01/15
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · PROPOFOL
- CriticalPropofol Injectable Emulsion Recalled for Particulate Matter Contamination
FDA (Drugs) · 2022-09-21
- SeverePropofol Injectable Emulsion Vials Recalled for Particulate Matter Contamination
FDA (Drugs) · 2022-08-03
- SevereHospira Recalls Propofol Injectable Emulsion Due to Temperature Excursions
FDA (Drugs) · 2015-02-25
- SevereHospira Recalls Propofol Injectable Vials Due to Embedded Particulate Matter
FDA (Drugs) · 2015-02-04
- SevereHospira Recalls Propofol Vials Due to Metallic Particulate Matter
FDA (Drugs) · 2014-08-27
Same manufacturer · Hospira Inc.
See all →- CriticalHospira Recalls Dextrose Injection Syringes Due to Human Hair Particulate
FDA (Drugs) · 2017-05-31
- ModerateHospira Recalls Minibore Extension Sets Due to Solvent Occlusion
FDA (Devices) · 2017-01-18
- LowHospira Recalls Lidocaine and Dextrose Injection for Stability Failures
FDA (Drugs) · 2016-12-14
- SevereHospira Recalls Fentanyl Citrate Injection Ampules Due to Broken Tips
FDA (Drugs) · 2016-11-30
- HighHospira Symbiq Infusion Pump Recall for White Screen Safety Shutdown
FDA (Devices) · 2016-11-16
Same hazard · particulate matter
See all →- SevereACTHAR Gel Recalled for Presence of Glass and Stopper Particulate Matter
FDA (Drugs) · 2026-09-02
- SevereB. Braun Recalls Lactated Ringer's Injection Due to Particulate Matter
FDA (Drugs) · 2026-09-02
- CriticalAmerican Regent Recalls Papaverine Hydrochloride Injection Due to Particulate Matter
FDA (Drugs) · 2026-08-26
- SevereAmerican Regent Recalls Nitroglycerin Injection Due to Particulate Matter
FDA (Drugs) · 2026-08-26
- SevereAmerican Regent Recalls Cyanocobalamin Injections Due to Particulate Matter
FDA (Drugs) · 2026-08-26